ACTRN12612001233819已完成未知
A double-blind, randomised, placebo controlled study of 12 weeks of oral vitamin D supplementation on strength, speed and body composition in elite rugby union players residing in Southern New Zealand.
Dr Kirsty Fairbairn0 个研究点目标入组 60 人开始时间: 2012年11月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 40 Years（—）
- 性别
- Male
入选标准
- •Rugby players training in the Otago and Southland ITM Cup pre-season training squads, including development players.
- •Aged 18 years and over, and able to undergo strength and speed testing.
排除标准
- •Aged under 18 years of age; currently taking Vitamin D supplements; the presence of any chronic disease such as heart disease, diabetes or cancer; the presence of any conditions that affect hormone metabolism (primarily growth hormone and insulin metabolism); smokers.
研究者
相似试验
进行中（未招募）
1 期
A double-blind, randomised, placebo controlled study to evaluate the safety and efficacy of A-60444 in adults with RSV infection following stem cell transplantatiopper respiratory tract infection (as identified by regular surveillance of stem cell transplant patients) or stem cell transplant patients diagnosed as positive for respiratory syncytial virus (RSV).MedDRA version: 7.0Level: LLTClassification code 10061603EUCTR2004-003657-99-GBArrow Therapeutics Ltd22
进行中（未招募）
1 期
A double-blind, randomised, placebo controlled study to investigate chronic intermittent pulse” therapy of moxifloxacin as a prevention of acute exacerbation in out-patients with chronic bronchitis. - PULSEClassification code 10008841Chronic bronchitisEUCTR2004-000404-40-ESBayer plc
进行中（未招募）
1 期
A double-blind, randomised, placebo controlled study to investigate chronic intermittent pulse” therapy of moxifloxacin as a prevention of acute exacerbation in out-patients with chronic bronchitis. - PULSEChronic bronchitisEUCTR2004-000404-40-IEBayer plc
进行中（未招募）
不适用
A randomised, double-blind, placebo controlled study to assess the safety and the efficacy of neridronate 100 mg - 4 i.v. infusions in a course of 10 days treatment - in patients with algodystrophic syndrome. - NDEUCTR2007-003372-18-ITABIOGEN PHARMA
进行中（未招募）
不适用
A randomised, double-blind, placebo controlled study to evaluate the pharmacodynamics, safety, tolerability and pharmacokinetics profile of SLx-4090 over 14 days dosing in subjects with high triglyceride values.Dyslipidemia/hypertriglyceridemiaMedDRA version: 8.1Level: LLTClassification code 10058110Term: DyslipidemiaEUCTR2007-000536-95-DESurface Logix